Metformin's contraindications should be contraindicated.
作者信息
McCormack James, Johns Kevin, Tildesley Hugh
机构信息
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC.
出版信息
CMAJ. 2005 Aug 30;173(5):502-4. doi: 10.1503/cmaj.045292.
Abstract
摘要
相似文献
1
Metformin's contraindications should be contraindicated.
CMAJ. 2005 Aug 30;173(5):502-4. doi: 10.1503/cmaj.045292.
2
Metformin in type 2 diabetes.
J Fam Pract. 2004 Nov;53(11):900.
3
Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?
BMJ. 2007 Sep 8;335(7618):508-12. doi: 10.1136/bmj.39255.669444.AE.
4
Risk factors for metformin-associated lactic acidosis.
WMJ. 1999 Jul-Aug;98(4):56-7.
5
[Does a reduced kidney function (creatinine clearance 10-15 ml/min), without acidosis, increase the risk for the rise of lactic acidosis caused by metformin?].
Ned Tijdschr Geneeskd. 2002 Nov 16;146(46):2213.
6
Metformin use in decompensated heart failure.
Cardiol Rev. 2008 Sep-Oct;16(5):269-72. doi: 10.1097/CRD.0b013e3181846c53.
7
Metformin-associated lactic acidosis in type 2 diabetes mellitus: incidence and presentation in common clinical practice.
Nephrol Dial Transplant. 2008 Jul;23(7):2436-8. doi: 10.1093/ndt/gfn152. Epub 2008 Apr 3.
8
The safety of metformin in heart failure.
Ann Pharmacother. 2007 Apr;41(4):642-6. doi: 10.1345/aph.1H523. Epub 2007 Mar 20.
9
[Metformin-associated lactic acidosis with acute renal failure in type 2 diabetes mellitus]].
Med Klin (Munich). 2002 Jul 15;97(7):435; author reply 436.
10
[Classic drug in diabetes therapy. Revise contraindications?].
MMW Fortschr Med. 2007 May 31;149(22):14.
引用本文的文献
1
Assessing the incidence of acidosis in patients receiving metformin with and without risk factors for lactic acidosis.
Ther Adv Chronic Dis. 2018 Jun 13;9(9):179-190. doi: 10.1177/2040622318779760. eCollection 2018 Sep.
2
Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis.
BMC Cancer. 2018 Apr 18;18(1):438. doi: 10.1186/s12885-018-4334-5.
3
Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action.
Pharmaceuticals (Basel). 2010 Sep 15;3(9):3005-3020. doi: 10.3390/ph3093005.
4
Retrospective analysis of lactic acidosis-related parameters upon and after metformin discontinuation in patients with diabetes and chronic kidney disease.
Int Urol Nephrol. 2016 Aug;48(8):1305-1312. doi: 10.1007/s11255-016-1288-x. Epub 2016 Apr 21.
5
Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?
J Diabetes Res. 2016;2016:7502489. doi: 10.1155/2016/7502489. Epub 2016 Jan 6.
6
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
J Clin Med. 2015 Oct 23;4(10):1866-89. doi: 10.3390/jcm4101866.
7
Use of Renally Inappropriate Medications in Older Veterans: A National Study.
J Am Geriatr Soc. 2015 Nov;63(11):2290-7. doi: 10.1111/jgs.13790. Epub 2015 Oct 27.
8
Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.
Clin Interv Aging. 2014 Nov 18;9:1963-80. doi: 10.2147/CIA.S53482. eCollection 2014.
9
Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney disease.
Clin Kidney J. 2012 Feb;5(1):65-67. doi: 10.1093/ndtplus/sfr134.
10
Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: a historical cohort comparing the use of metformin in Quebec pre and post-Canadian Diabetes Association guidelines.
BMC Health Serv Res. 2013 Oct 25;13:442. doi: 10.1186/1472-6963-13-442.
本文引用的文献
1
Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.
Diabetes Care. 2005 Jan;28(1):154-63. doi: 10.2337/diacare.28.1.154.
2
No evidence for a reduction of myocardial infarctions by acarbose.
Eur Heart J. 2004 Jul;25(13):1179; author reply 1179-80. doi: 10.1016/j.ehj.2004.01.026.
3
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
Eur Heart J. 2004 Jan;25(1):10-6. doi: 10.1016/s0195-668x(03)00468-8.
4
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis.
Arch Intern Med. 2003 Nov 24;163(21):2594-602. doi: 10.1001/archinte.163.21.2594.
5
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
JAMA. 2003 Jul 23;290(4):486-94. doi: 10.1001/jama.290.4.486.
6
Contraindications to the use of metformin.
BMJ. 2003 Jan 4;326(7379):4-5. doi: 10.1136/bmj.326.7379.4.
7
Lactic acidemia associated with metformin.
Ann Pharmacother. 2003 Jan;37(1):66-9. doi: 10.1345/aph.1C183.
8
Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy.
Arch Intern Med. 2002 Feb 25;162(4):434-7. doi: 10.1001/archinte.162.4.434.
9
Metformin-associated lactic acidosis in a low risk patient.
Can J Clin Pharmacol. 2001 Summer;8(2):104-6.
10
Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines.
Diabet Med. 2001 Jun;18(6):483-8. doi: 10.1046/j.1464-5491.2001.00509.x.
Zotero 插件